{"product_id":"lemaitre-pestle-analysis","title":"LeMaitre Vascular PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain competitive insight with our PESTLE Analysis of LeMaitre Vascular—spot regulatory, economic, and technological drivers that shape strategy and valuation; ideal for investors and strategists seeking concise, actionable intelligence. Purchase the full report to access detailed risk assessments, market implications, and editable charts for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Healthcare Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, US and European payers accelerate value-based care; Medicare’s VBID and CMS payment reforms link reimbursement to outcomes, pressuring medtech to demonstrate cost-effectiveness—studies showing 15–25% higher up-front device costs must be offset by reduced readmissions. LeMaitre must provide real-world evidence and health-economic data to maintain coverage across public programs where procedural budgets face 3–5% annual constraints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Tariff Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrade tensions between the United States and China remain critical for medical device firms; in 2024 US tariffs on certain components rose to 7.5–25%, affecting catheter\/graft input costs and contributing to a 4–6% increase in manufacturing expenses for some suppliers. Fluctuating export controls and Section 301 reviews risk market access, with China accounting for ~12% of global vascular device demand in 2023. LeMaitre must keep agile sourcing and dual-shore strategies to protect margins and limit supply disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe political drive for regulatory harmonization—exemplified by EU-US discussions and WHO’s 2024 Global Medical Device Regulatory Toolkit—aims to cut approval times by up to 30%, benefiting LeMaitre Vascular’s CE\/FDA-aligned portfolio. \u003c\/p\u003e\n\u003cp\u003eNevertheless, conflicting political priorities in key emerging markets like India and Brazil caused median market entry delays of 9–14 months in 2023–2024, creating localized barriers for new vascular devices. \u003c\/p\u003e\n\u003cp\u003eLeMaitre tracks geopolitical regulatory shifts and reallocates R\u0026amp;D and commercial resources to optimize international launch timing, targeting a 15% faster rollout across 12 priority markets by 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding for Specialized Surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical decisions on national health budgets shape public hospital vascular surgery volumes; EU public health spending fell 0.8% real in 2023 in some states, risking fewer elective procedures.\u003c\/p\u003e\n\u003cp\u003eRising investment in geriatric care and chronic disease programs—EU geriatrics funding up ~3% in 2024—boosts demand for peripheral vascular interventions, benefiting device makers like LeMaitre Vascular.\u003c\/p\u003e\n\u003cp\u003eConversely, austerity in parts of Southern Europe reduced elective vascular surgeries by ~5–10% in 2023, pressuring sales in those markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealth budget shifts directly affect procedure volumes\u003c\/li\u003e\n\u003cli\u003e+3% geriatrics\/chronic care funding (2024) increases peripheral vascular demand\u003c\/li\u003e\n\u003cli\u003e0.8% public health spend decline (2023) and −5–10% elective surgeries in some regions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in Manufacturing Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical stability in key manufacturing hubs like Costa Rica and Ireland—which together accounted for about 35% of LeMaitre Vascular’s 2024 manufacturing footprint—is critical to steady supply of biological and synthetic grafts.\u003c\/p\u003e\n\u003cp\u003eRegional unrest or sudden governance shifts risk creating logistic bottlenecks, as seen in 2023 global supply disruptions that raised lead times ~18% for medical-device components industry-wide.\u003c\/p\u003e\n\u003cp\u003eLeMaitre’s strategy emphasizes geographic diversification, maintaining multiple production sites and supplier redundancy to reduce concentration risk and operational exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% manufacturing concentration in Costa Rica\/Ireland (2024)\u003c\/li\u003e\n\u003cli\u003eIndustry lead-time spikes ~18% during 2023 disruptions\u003c\/li\u003e\n\u003cli\u003eGeographic diversification and supplier redundancy to mitigate political risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shocks: tariffs, VBID cost pressures, approvals cut ~30%, 35% Mfg concentrated\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors: value-based reimbursement pressures (VBID\/CMS) force cost-effectiveness evidence; US–China tariffs (7.5–25% in 2024) raised input costs ~4–6%; regulatory harmonization may cut approvals ~30%; emerging-market entry delays 9–14 months; public health spend shifts (EU −0.8% 2023; geriatrics +3% 2024) alter procedure volumes; 35% manufacturing in Costa Rica\/Ireland.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariffs\u003c\/td\u003e\n\u003ctd\u003e7.5–25% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket delays\u003c\/td\u003e\n\u003ctd\u003e9–14 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing concentration\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect LeMaitre Vascular across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats, opportunities, and forward-looking scenarios for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of LeMaitre Vascular that’s easy to drop into presentations or planning decks, helping teams quickly align on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 the medical device sector still absorbs elevated input costs, with US producer prices for chemicals and allied products up about 12% since 2021 and medical-grade polymer prices rising ~8% in 2024–25, forcing LeMaitre Vascular to raise prices selectively to protect margins.\u003c\/p\u003e\n\u003cp\u003eSpecialized labor scarcity has pushed related wages up ~6% CAGR 2022–25, increasing production costs for grafts using bovine tissue and polymer components.\u003c\/p\u003e\n\u003cp\u003ePassing these increases to hospital systems is constrained: 60% of hospitals report tighter capital budgets in 2024–25, making reimbursement and procurement pressure the main economic challenge for LeMaitre.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForeign Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs ~40% of LeMaitre Vasculars 2024 revenue was generated outside the US, Euro and major-currency swings materially affect reported sales; a 10% USD appreciation would lower translated revenue by roughly 4 percentage points. USD strength also pressures overseas pricing competitiveness, potentially compressing margins. The company uses forward hedges and localized manufacturing\/sales entities to mitigate recurring FX exposures, with hedges covering a portion of forecasted cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate and Capital Cost Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe prevailing interest rate environment—US Fed funds at 5.25–5.50% as of Dec 2025—raises LeMaitre Vascular’s weighted average cost of capital, increasing financing costs for acquisitions and R\u0026amp;D; rates have stabilized from 2022–23 peaks but remain above pre‑pandemic levels. Strategic cash flow management and a strong net cash position (cash + equivalents reported $XXm in FY2024) are prioritized to fund niche acquisitions while limiting reliance on expensive debt. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Budgetary Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic pressures force hospitals into stricter procurement and inventory cuts; US hospital operating margins fell to 1.6% in 2023, pushing sharper cost controls and just-in-time stocking.\u003c\/p\u003e\n\u003cp\u003eUse of group purchasing organizations grew—GPOs account for roughly 70% of hospital supply spend in the US—pressuring unit prices for high-volume vascular devices.\u003c\/p\u003e\n\u003cp\u003eLeMaitre must show clinical superiority and cost-effectiveness (e.g., lower complication\/readmission rates) to preserve pricing versus generics and low-cost competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS hospital margins 2023: 1.6%\u003c\/li\u003e\n\u003cli\u003eGPO share of spend: ~70%\u003c\/li\u003e\n\u003cli\u003eFocus: inventory reduction, value-based differentiation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Emerging Market Economies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising middle-class populations in Asia and Latin America—projected to reach 3.3 billion by 2030—expand demand for vascular care; LeMaitre can capitalize as percutaneous and surgical procedures grow with aging demographics.\u003c\/p\u003e\n\u003cp\u003eHealthcare spending in emerging markets rose ~6% CAGR 2018–2023, and increased hospital investments signal higher demand for sophisticated surgical tools like LeMaitre’s devices.\u003c\/p\u003e\n\u003cp\u003eLeMaitre is assessing economic viability of expanding direct sales in high-growth territories, weighing higher margins against incremental SG\u0026amp;A and 2024 regional revenue trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMiddle-class expansion to 2030 boosts addressable market\u003c\/li\u003e\n\u003cli\u003eEmerging-market healthcare spend ~6% CAGR (2018–2023)\u003c\/li\u003e\n\u003cli\u003eStrategic evaluation of direct-sales expansion amid 2024 regional revenue data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput inflation, wage pressure and FX headwinds squeeze margins as rates rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds—input inflation (medical polymers +8% 2024–25), wage pressure (~6% CAGR 2022–25), tight hospital budgets (60% reporting cuts) and GPO pricing (≈70% spend)—compress margins; FX volatility (40% revenue ex‑US; 10% USD appreciation ≈4ppt revenue hit) and higher rates (Fed 5.25–5.50% Dec‑2025) raise WACC and financing costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolymers inflation\u003c\/td\u003e\n\u003ctd\u003e+8% (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage CAGR\u003c\/td\u003e\n\u003ctd\u003e~6% (2022–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals cutting capex\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO spend\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue ex‑US\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD 10% ↑ impact\u003c\/td\u003e\n\u003ctd\u003e−4ppt rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (Dec‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eLeMaitre Vascular PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact LeMaitre Vascular PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751620555129,"sku":"lemaitre-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lemaitre-pestle-analysis.png?v=1772233456","url":"https:\/\/growthsharematrix.com\/products\/lemaitre-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}